Meeder Asset Management Inc. Buys New Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Meeder Asset Management Inc. bought a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 6,852 shares of the biopharmaceutical company’s stock, valued at approximately $39,000.

Several other hedge funds have also bought and sold shares of VNDA. Aristides Capital LLC acquired a new stake in Vanda Pharmaceuticals in the 4th quarter valued at about $272,000. GSA Capital Partners LLP lifted its position in Vanda Pharmaceuticals by 39.8% during the fourth quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock worth $2,396,000 after acquiring an additional 161,737 shares during the last quarter. Los Angeles Capital Management LLC lifted its position in Vanda Pharmaceuticals by 17.6% during the first quarter. Los Angeles Capital Management LLC now owns 431,224 shares of the biopharmaceutical company’s stock worth $1,772,000 after acquiring an additional 64,670 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Vanda Pharmaceuticals by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 4,387 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Vanda Pharmaceuticals by 70.1% during the first quarter. BNP Paribas Financial Markets now owns 101,363 shares of the biopharmaceutical company’s stock worth $417,000 after acquiring an additional 41,767 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Trading Up 2.2 %

NASDAQ VNDA opened at $5.10 on Monday. Vanda Pharmaceuticals Inc. has a 1-year low of $3.30 and a 1-year high of $6.75. The company has a 50 day moving average of $5.48 and a 200-day moving average of $5.11. The company has a market cap of $296.81 million, a price-to-earnings ratio of -63.75 and a beta of 0.77.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The business had revenue of $50.47 million during the quarter. On average, equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -0.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald raised their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research report on Saturday. They set a “hold” rating for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.